Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*
Jean‐Louis Vincent(Université Libre de Bruxelles), Jonathan Janes(Eli Lilly (United States)), David P. Sundin, Antonio Artigas(Instituto de Salud Carlos III), William L. Macias(Myovant Sciences (United States)), Christian Putensen(University Hospital Bonn), Mary Ann Turlo, Roberto Fumagalli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Gordon R. Bernard(Vanderbilt University Medical Center), Theressa J. Wright, Richard Beale(St Thomas' Hospital), Jean-François Dhainaut, Christopher J. Doig(Alberta Health Services), Kar Wong
Cited by 321
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k